Myostatin Exacerbates Endothelial Dysfunction Induced by Uremic Toxin Indoxyl Sulfate and Is Associated with Hemodialysis Arteriovenous Access Complications
Toxins · 2025
DOI: 10.3390/toxins17040159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Justine Solignac und 10 weiteren Autor:innen. Beteiligte Einrichtung: C2VN, Aix-Marseille University, INSERM, INRAE, 13385 Marseille, France. Hauptthemen laut MEDLINE: Indican, Renal Dialysis, Myostatin, Uremic Toxins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Société Francophone de Néphrologie Dialyse et Transplantation (SFNDT).
Abstract (Originalsprache)
Hemodialysis patients exhibit endothelial dysfunction, contributing to elevated cardiovascular risk and complications of the arteriovenous access. These patients have elevated serum levels of myostatin, a member of the transforming growth factor-β (TGFβ) superfamily, and of the uremic toxin indoxyl sulfate, both of which are pro-inflammatory towards endothelial cells. We hypothesized that myostatin and indoxyl sulfate may synergistically induce endothelial dysfunction by impairing endothelial proliferation and promoting a pro-inflammatory phenotype. We first investigated the effect of myostatin on cultured endothelial cells in the presence of indoxyl sulfate. We then examined the association between serum myostatin concentrations and the occurrence of cardiovascular and arteriovenous access complications in hemodialysis patients. In vitro, myostatin exhibited endotheliotoxic effects in the presence of a uremic concentration of indoxyl sulfate, enhanced its antiproliferative effect, and amplified MCP-1 and IL-8 chemokine upregulation. In patients, high myostatin concentrations correlated with indoxyl sulfate concentrations and were associated with an increased risk of arteriovenous access complications. These findings suggest that myostatin amplifies endothelial injury mediated by indolic uremic toxins and might contribute to AV access complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- C2VN, Aix-Marseille University, INSERM, INRAE, 13385 Marseille, France.
- Centre de Néphrologie et Transplantation Rénale, APHM, Hôpital Conception, 13005 Marseille, France.
- Phocean Nephrology Institute, Clinique Bouchard, ELSAN, 13005 Marseille, France.
- APHM, Hop Timone, Public Health Department (BIOSTIC), 13005 Marseille, France.
- Aix-Marseille University, INSERM, IRD, ISSPAM, SESSTIM, 13451 Marseille, France.
ORCID-Profile: Justine Solignac, Laetitia Dou, Nathalie Pedinielli, Julien Mancini, Stéphane Burtey, Stanislas Bataille
Förderung
- CSRD VA
- Société Francophone de Néphrologie Dialyse et Transplantation (SFNDT)
Zitieren
APA
Solignac, J., Dou, L., Chermiti, R., McKay, N., Giaime, P., Pedinielli, N., Benjelloun, H., Lano, G., Mancini, J., Burtey, S., & Bataille, S. (2025). Myostatin Exacerbates Endothelial Dysfunction Induced by Uremic Toxin Indoxyl Sulfate and Is Associated with Hemodialysis Arteriovenous Access Complications. Toxins. https://doi.org/10.3390/toxins17040159
Vancouver
Solignac J, Dou L, Chermiti R, McKay N, Giaime P, Pedinielli N, et al. Myostatin Exacerbates Endothelial Dysfunction Induced by Uremic Toxin Indoxyl Sulfate and Is Associated with Hemodialysis Arteriovenous Access Complications. Toxins. 2025. doi:10.3390/toxins17040159
BibTeX
@article{Solignac2025,
author = {Solignac, Justine and Dou, Laetitia and Chermiti, Rania and McKay, Nathalie and Giaime, Philippe and Pedinielli, Nathalie and Benjelloun, Hamza and Lano, Guillaume and Mancini, Julien and Burtey, Stéphane and Bataille, Stanislas},
title = {Myostatin Exacerbates Endothelial Dysfunction Induced by Uremic Toxin Indoxyl Sulfate and Is Associated with Hemodialysis Arteriovenous Access Complications},
journal = {Toxins},
year = {2025},
doi = {10.3390/toxins17040159}
}
EUVIMED